Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission...
Teligent is a specialty generic pharmaceutical ...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
We are a pharmaceutical company dedicated to the development of best-in-class ther...
We are a pharmaceutical company dedicated to th...
ProPhase Labs is a diversified medical science and technology company. We develop,...
ProPhase Labs is a diversified medical science ...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focu...
Paratek Pharmaceuticals, Inc. is a commercial-s...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
Join the National Investor Network and get the latest information with your interests in mind.